BeOne Medicines' fourth quarter revenue of $1.5B beats estimates, driven by 38% growth in flagship drug BRUKINSA.

BeOne Medicines reported fourth quarter 2025 revenue of $1.5 billion, up 33% year-over-year, and non-GAAP diluted EPS of $1.95, beating analyst estimates. For the full year 2025, revenue increased 40% to $5.3 billion. The company guided for full-year 2026 revenue between $6.2 billion and $6.4 billion.

Key Highlights

• Global sales of BRUKINSA, the company's flagship BTK inhibitor, reached $1.1 billion for the quarter, an increase of 38% compared to the prior-year period.
• The company achieved full-year GAAP profitability for the first time, reporting net income of $287 million for 2025, a significant turnaround from a $645 million loss in 2024.
• Management issued initial full-year 2026 revenue guidance of $6.2 billion to $6.4 billion, implying continued strong growth.